Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Clinical binding properties, internalization kinetics, and clinicopathologic activity of brentuximab vedotin: an antibody-drug conjugate for CD30-positive lymphoid neoplasms.

× No keyword cloud information.

10 in total

1. CD30 is a potential therapeutic target in malignant mesothelioma.

Authors: Snehal Dabir; Adam Kresak; Michael Yang; Pingfu Fu; Gary Wildey; Afshin Dowlati
Journal: Mol Cancer Ther Date: 2015-01-14 Impact factor: 6.261

Review 2. The expanding role of prodrugs in contemporary drug design and development.

Authors: Jarkko Rautio; Nicholas A Meanwell; Li Di; Michael J Hageman
Journal: Nat Rev Drug Discov Date: 2018-04-27 Impact factor: 84.694

3. CD30 targeting with brentuximab vedotin: a novel therapeutic approach to primary effusion lymphoma.

Authors: Shruti Bhatt; Brittany M Ashlock; Yasodha Natkunam; Victoria Sujoy; Jennifer Rose Chapman; Juan Carlos Ramos; Enrique A Mesri; Izidore S Lossos
Journal: Blood Date: 2013-07-09 Impact factor: 22.113

Review 4. Marine anticancer drugs and their relevant targets: a treasure from the ocean.

Authors: Manisha Nigam; Hafiz Ansar Rasul Suleria; Mohammad Hosein Farzaei; Abhay Prakash Mishra
Journal: Daru Date: 2019-06-05 Impact factor: 3.117

Review 5. Treatment of relapsed classical Hodgkin lymphoma in the brentuximab vedotin era.

Authors: Solomon A Graf; Ajay K Gopal
Journal: Hematology Am Soc Hematol Educ Program Date: 2014-11-18

6. Evolving Strategies for Target Selection for Antibody-Drug Conjugates.

Authors: Marc Damelin; Wenyan Zhong; Jeremy Myers; Puja Sapra
Journal: Pharm Res Date: 2015-01-15 Impact factor: 4.580

Review 7. Marine-Derived Pharmaceuticals - Challenges and Opportunities.

Authors: Ulrike Lindequist
Journal: Biomol Ther (Seoul) Date: 2016-11-01 Impact factor: 4.634

Review 8. Antibody-Drug Conjugates for Cancer Therapy.

Authors: Adam C Parslow; Sagun Parakh; Fook-Thean Lee; Hui K Gan; Andrew M Scott
Journal: Biomedicines Date: 2016-07-11

Review 9. Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required?

Authors: Alexander H Staudacher; Michael P Brown
Journal: Br J Cancer Date: 2017-10-24 Impact factor: 7.640

Review 10. Brentuximab Vedotin: A Review in CD30-Positive Hodgkin Lymphoma.

Authors: Lesley J Scott
Journal: Drugs Date: 2017-03 Impact factor: 9.546

10 in total